Anzeige
❌
Mehr »
Dienstag, 13.10.2026 - Börsentäglich über 12.000 News
35 Millionen C$ Einsatz gegenüber 13 Millionen C$ erwartetem Gewinn für 2027
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PGLV | ISIN: IE00BFY8C754 | Ticker-Symbol: 2TG
Tradegate
08.10.26 | 09:30
182,80 Euro
-6,92 % -13,60
Branche
Gesundheitswesen
Aktienmarkt
USA 500
1-Jahres-Chart
STERIS PLC Chart 1 Jahr
5-Tage-Chart
STERIS PLC 5-Tage-Chart
RealtimeGeldBriefZeit
191,60199,5010:06
191,60199,5010:06
PR Newswire
66 Leser
Artikel bewerten:
(0)

Xodus Medical Announces Agreement to Be Acquired by STERIS (NYSE: STE)

PITTSBURGH, Oct. 12, 2026 /PRNewswire/ -- Xodus Medical, a leading developer and manufacturer of innovative surgical safety solutions, today announced that it has entered into an agreement to be acquired by STERIS, a global provider of products and services that support patient care with an emphasis on infection prevention.

The acquisition represents a significant milestone in Xodus Medical's more than 30-year history, bringing together two organizations with a shared commitment to advancing patient safety, supporting healthcare professionals, and delivering innovative solutions to the surgical environment. As part of a larger global organization, Xodus Medical looks forward to expanding its reach, leveraging complementary capabilities, and delivering even greater value to its customers.

Equally important is the strong cultural alignment between the two companies. Both organizations share a dedication to product excellence, continuous improvement, and building lasting relationships with the healthcare professionals they serve. "Joining STERIS represents an exciting new chapter for Xodus Medical and an opportunity to build upon everything our talented team has accomplished over the past three decades," said Craig Kaforey, Chief Executive Officer of Xodus Medical. "Together, we see tremendous potential to deliver even greater value to our customers by combining our innovative products and expertise with STERIS's extensive resources, industry knowledge, and established market presence. Just as importantly, we believe our shared values and commitment to excellence will create meaningful opportunities for our employees to grow and develop as part of a global organization. I am incredibly proud of what our team has accomplished and excited about what lies ahead."

STERIS is approximately $6 billion in revenue, with 18,000 Associates focused on providing innovative healthcare and life science products and services around the globe. "Xodus Medical's product portfolio complements and expands STERIS's offering, particularly by adding consumables used in the operating room. Its focus on products that make surgery safer aligns closely with our mission to help our Customers create a healthier and safer world," said Dan Carestio, President and Chief Executive Officer of STERIS. "The business has demonstrated an ability to grow at double-digit rates with its specialty product portfolio, a steady stream of new products, and a highly effective commercial team. We look forward to welcoming the Xodus Medical team to STERIS and working together to enhance our service to our customers and value for our shareholders."

Throughout its history, Xodus Medical has remained focused on its mission of Making Surgery Safer. The company believes joining STERIS will further strengthen its ability to support healthcare providers with differentiated solutions that enhance patient safety and improve surgical outcomes.

Advisors

Goldman Sachs & Co. LLC is serving as exclusive financial advisor to STERIS, and Jones Day is serving as legal counsel. J.P. Morgan is serving as exclusive financial advisor to Xodus Medical, and Morgan, Lewis & Bockius LLP is serving as legal counsel.

About STERIS

STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. For more information, visit www.steris.com.

About Xodus Medical

Founded in 1993 and headquartered near Pittsburgh, Pennsylvania, Xodus Medical is a leading developer and manufacturer of innovative medical devices dedicated to Making Surgery Safer. The company's comprehensive portfolio of proprietary surgical safety technologies, including its flagship Pink Pad® patient positioning systems, serves hospitals worldwide. Xodus Medical has established itself as a trusted partner to healthcare professionals and a recognized leader in perioperative patient safety. For more information, visit www.xodusmedical.com.

SOURCE Xodus Medical

© 2026 PR Newswire
KI-Euphorie kippt - Bei diesen 5 Aktien droht der Crash!
Drei Jahre lang kannten KI-Aktien fast nur eine Richtung: nach oben. Billionenschwere Investitionspläne von Alphabet, Amazon, Meta und Microsoft haben Halbleiter- und Infrastrukturwerte auf immer neue Höhen getrieben. Doch jetzt bekommt die Erfolgsstory gefährliche Risse.

Steigende Anleiherenditen verteuern die Finanzierung, während die gewaltigen KI-Ausgaben zunehmend nicht mehr aus den laufenden Cashflows bezahlt werden können. Gleichzeitig zeigen günstigere chinesische Modelle, dass leistungsfähige KI womöglich mit deutlich weniger Rechenleistung auskommt. Damit wächst die Gefahr, dass heute für Milliarden errichtete Kapazitäten morgen nicht die erhofften Renditen liefern.

Für Anleger könnte das zum Problem werden. Denn treffen steigende Finanzierungskosten auf Überkapazitäten und enttäuschende Cashflows, geraten gerade hoch bewertete KI-Profiteure schnell unter Druck. Aus den größten Gewinnern der vergangenen Jahre könnten so die größten Verlierer der nächsten Korrektur werden.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, bei denen das Chance-Risiko-Verhältnis jetzt besonders gefährlich erscheint – und bei denen Anleger genauer hinschauen sollten.

Jetzt den kostenlosen Report sichern – bevor die KI-Euphorie ihren nächsten Realitätstest erlebt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.